• Maura L Furey, Wayne C Drevets, Joanna Szczepanik, Ashish Khanna, Allison Nugent, and Carlos A Zarate.
• Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute on Mental Health, National Institutes of Health, Bethesda, MD (Dr Furey, Ms Szczepanik, Dr Nugent, and Dr Zarate); Janssen Pharmaceuticals, LLC, of Johnson & Johnson, Inc., Titusville, NJ (Dr Drevets); Physical Medicine & Rehabilitation, Jewish Medical Center, Brooklyn Hospital Center, Brooklyn, NY (Dr Khanna).Registry number NCT00055575. mfurey@mail.nih.gov.
• Int. J. Neuropsychopharmacol. 2015 Mar 28; 18 (8).

BackgroundFaster acting antidepressants and biomarkers that predict treatment response are needed to facilitate the development of more effective treatments for patients with major depressive disorders. Here, we evaluate implicitly and explicitly processed emotional faces using neuroimaging to identify potential biomarkers of treatment response to the antimuscarinic, scopolamine.MethodsHealthy participants (n=15) and unmedicated-depressed major depressive disorder patients (n=16) participated in a double-blind, placebo-controlled crossover infusion study using scopolamine (4 μg/kg). Before and following scopolamine, blood oxygen-level dependent signal was measured using functional MRI during a selective attention task. Two stimuli comprised of superimposed pictures of faces and houses were presented. Participants attended to one stimulus component and performed a matching task. Face emotion was modulated (happy/sad) creating implicit (attend-houses) and explicit (attend-faces) emotion processing conditions. The pretreatment difference in blood oxygen-level dependent response to happy and sad faces under implicit and explicit conditions (emotion processing biases) within a-priori regions of interest was correlated with subsequent treatment response in major depressive disorder.ResultsCorrelations were observed exclusively during implicit emotion processing in the regions of interest, which included the subgenual anterior cingulate (P<.02) and middle occipital cortices (P<.02).ConclusionsThe magnitude and direction of differential blood oxygen-level- dependent response to implicitly processed emotional faces prior to treatment reflect the potential to respond to scopolamine. These findings replicate earlier results, highlighting the potential for pretreatment neural activity in the middle occipital cortices and subgenual anterior cingulate to inform us about the potential to respond clinically to scopolamine.Published by Oxford University Press on behalf of CINP 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.

38 keywords...

hide…